Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.

Heart Failure Clinical Trial

— RASP-HF  

Official title:

Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients: a Pilot Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02149940
• Other study ID #: S55301
• Status: Completed
• Phase: N/A
• First received: May 26, 2014
• Last updated: May 26, 2014
• Start date: April 2013
• Est. completion date: October 2013

Study information

• Verified date: May 2014
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
• Study type: Interventional

Clinical Trial Summary

Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted.

In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: October 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• 75 years or older

• diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure'

• diagnosis had to be confirmed by a recent echocardiogram

Exclusion Criteria:

• not Dutch speaking

• treatment restrictions had been applied on admission

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Heart Failure

Intervention

Other:
• heart-failure related pharmaceutical intervention

Locations

Country	Name	City	State
Belgium	University Hospitals Leuven	Leuven	Flemish Brabant

Sponsors (1)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the number of heart-failure related pharmaceutical interventions		during hospital stay (average of 14 days)	No
Secondary	acceptance rate of the pharmaceutical interventions		during hospital stay (average of 14 days)	No
Secondary	clinical feasibility of the accepted interventions		during hospital stay (average of 14 days)	Yes